Tharimmune (THAR) Stock Price, News & Analysis

Company Overview

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Key Stats

• Today's Range: $2.04 to $2.13
• 50-Day Range: $1.95 to $3.43
• 52-Week Range: $1.84 to $8.42
• Volume: 7,479 shs
• Average Volume: 346,162 shs
• Market Capitalization: $3.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Strong Buy

Tharimmune Stock Analysis - MarketRank™

Tharimmune scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Tharimmune has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tharimmune has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Tharimmune has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.16% of the float of Tharimmune has been sold short.

Short Interest Ratio / Days to Cover

Tharimmune has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tharimmune has recently increased by 37.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tharimmune does not currently pay a dividend.

Dividend Growth

Tharimmune does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.16% of the float of Tharimmune has been sold short.

Short Interest Ratio / Days to Cover

Tharimmune has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tharimmune has recently increased by 37.38%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

Tharimmune has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.

MarketBeat Follows

2 people have added Tharimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Tharimmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought $34,727.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.37% of the stock of Tharimmune is held by insiders.

Percentage Held by Institutions

Only 1.16% of the stock of Tharimmune is held by institutions.

THAR Stock Analysis - Frequently Asked Questions

How have THAR shares performed this year?

Tharimmune's stock was trading at $2.03 on January 1st, 2025. Since then, THAR shares have increased by 3.0% and is now trading at $2.09.
View the best growth stocks for 2025 here.

When did Tharimmune's stock split?

Tharimmune shares reverse split before market open on Tuesday, May 28th 2024. The 1-15 reverse split was announced on Tuesday, May 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Tharimmune?

Shares of THAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Tharimmune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tharimmune investors own include Jiuzi (JZXN), Avenue Therapeutics (ATXI), Scinai Immunotherapeutics (SCNI), Adial Pharmaceuticals (ADIL), Sphere 3D (ANY), Vinco Ventures (BBIG) and Blackboxstocks (BLBX).

Company Calendar

• Today: 1/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:THAR
• Previous Symbol: NASDAQ:THAR
• CUSIP: N/A
• CIK: 1861657
• Web: www.hillstreambio.com
• Phone: 908-955-3140
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.00
• High Stock Price Target: $17.00
• Low Stock Price Target: $17.00
• Potential Upside/Downside: +713.4%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,320,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -167.63%
• Return on Assets: -130.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.35
• Quick Ratio: 2.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $195.44 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 1,490,000
• Free Float: 1,451,000
• Market Cap: $3.11 million
• Optionable: Not Optionable
• Beta: 1.29